Skip to main
FBLG

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics is taking a unique approach in leveraging fibroblasts as a therapeutic engine, demonstrating their ability to differentiate and form 3D structures with scalability and stability. This could potentially lead to more efficient and cost-effective manufacturing processes. Additionally, the company has a deep IP moat and is focused on developing treatments for chronic and degenerative diseases with unmet medical needs, setting it apart from other companies in the regenerative medicine and cell therapy space. With a strong pipeline, including upcoming proof-of-concept results for their Phase 1/2 trial in diabetic foot ulcers, and a recent reverse stock split and public offering in place, FibroBiologics is well-positioned for continued growth and success.

Bears say

FibroBiologics is facing questions about the potential success of their CYWC628 trial in DFU patients, with interim data expected in the first half of 2026. The trial will evaluate wound healing outcomes, efficacy of response, and safety parameters through clinical and imaging evaluations of 28 participants. The company's stock is likely to be negatively impacted as these questions may lead to doubts about the company's ability to successfully bring their products to market in a timely and profitable manner. Additionally, the company's financials may be strained as they continue to invest in clinical trials and research and development efforts.

Fibrobiologics Inc (FBLG) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.